Benzinga | Aug 24, 2020 07:02AM EDT

Terumo Cardiovascular And CytoSorbents Collaborate To Commercialize CytoSorb In Ten US Hotspot States Under Emergency Use Authorization For COVID-19

ANN ARBOR, Mich.and MONMOUTH JUNCTION, N.J., Aug. 24, 2020 /PRNewswire/ --Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ:CTSO), manufacturer of the CytoSorb(r) extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S. COVID-19 hotspot states including Alabama,Arizona, California, Georgia, Louisiana, Mississippi, New Mexico, Oregon, Texas, and Washington. CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.